Replies to post #395507 on Anavex Life Sciences Corp (AVXL)

[JKS3]

Since all the averages and SDs are provided, you can calculate all the numbers from how many SDs away for each cutoff.

[powerwalker]

Dr.Oph, thanks for joining the Anavex MB. I think this conclusion states it all:

CONCLUSIONS Lecanemab reduced markers of amyloid in early Alzheimer’s disease and resulted in moderately less decline on measures of cognition and function than placebo at 18 months but was associated with adverse events. Longer trials are warranted to determine the efficacy and safety of lecanemab in early Alzheimer’s disease. (Funded by Eisai and Biogen; Clarity AD ClinicalTrials.gov number, NCT03887455. opens in new tab.)

https://www.nejm.org/doi/full/10.1056/NEJMoa2212948?query=featured_neurology-neurosurgery

Peer review concludes more testing is needed. We'll see how the fda decides this Friday unless it postpones meeting due to heat from Congress and outsiders.

Speaking of another P3, lec should be the drug, not blarcamesine, sent back to do another P3, based on the peer review paper alone, which, of course, states the problem with this drug: dangerous to patient's health and little efficacy.

Let's hope Anavex and TGD release data early this coming week to show the fda and the world that there is a better option to brain bleeding and swelling drugs!

ANAVEX NOW ... RIGHT NOW ... MONO-STYLE ... for LIFE ... and for ALL AGES!!!

Extremely ...